Polar Asset Management Partners Inc., an investment fund manager based in Ontario, Canada, has filed an amended Schedule 13G/A with the Securities and Exchange Commission on February 12, 2024, indicating a change in its holdings in Conduit Pharmaceuticals. The filing reveals that Polar Asset Management now beneficially owns 950,000 shares of Conduit Pharmaceuticals, which are issuable upon the exercise of warrants, representing 1.3% of the company's class of common stock. This stake is solely managed by Polar Asset Management, with no shared voting or dispositive power. The filing, dated December 31, 2023, also certifies that the shares were not acquired for the purpose of changing or influencing the control of Conduit Pharmaceuticals.

Polar Asset Management Partners Inc., an investment fund manager based in Ontario, Canada, has filed an amended Schedule 13G/A with the Securities and Exchange Commission on February 12, 2024, indicating a change in its holdings in Conduit Pharmaceuticals. The filing reveals that Polar Asset Management now beneficially owns 950,000 shares of Conduit Pharmaceuticals, which are issuable upon the exercise of warrants, representing 1.3% of the company's class of common stock. This stake is solely managed by Polar Asset Management, with no shared voting or dispositive power. The filing, dated December 31, 2023, also certifies that the shares were not acquired for the purpose of changing or influencing the control of Conduit Pharmaceuticals.